Real-time 3D confirmation of complete ablation with margins as a local cure for colorectal liver metastases: the ACCLAIM trial.
Constantinos T Sofocleous, Matthew R Callstrom, Elena N Petre...
https://pubmed.ncbi.nlm.nih.gov/41013745/Actively Recruiting
Led by Society of Interventional Oncology · Updated on 2024-01-17
275
Participants Needed
7
Research Sites
4 weeks
Total Duration
Researchers are evaluating microwave ablation MWA as a potential curative treatment for patients with up to three colorectal liver metastases CLM, each measuring 2.5 cm or less. The study aims to show that MWA can achieve a local progression-free survival rate of at least 90% over two years. This international, prospective, multi-center trial focuses on establishing MWA as a preferred standard of care for selected liver metastases by ensuring adequate ablation margins. Participants will undergo MWA using any FDA cleared or CE marked device, targeting one to three liver metastases. The procedure aims to create an ablation zone with a minimum margin of 5.0 mm, ideally 10 mm, around each tumor to maximize local tumor control. Margin size will be measured immediately after ablation and again 4-8 weeks later using contrast-enhanced CT scans reviewed by an independent core lab with 3D imaging software. If margins less than 5 mm are found, repeat ablation may be performed within 30 days if safe. During the study, participants will be closely monitored with imaging and clinical assessments to evaluate local tumor progression and overall hepatic disease-free survival. Researchers will also track tumor coverage by the ablation zone and any serious adverse events within 90 days post-procedure. The primary outcome is local tumor progression-free survival at 24 months. Secondary outcomes include hepatic progression-free survival, overall survival, and safety measures. The total participation period aligns with these assessments over two years.
CONDITIONS
Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)
R
Research Manager
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Society of Interventional Oncology
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Margin‑confirmed Microwave Ablation | Surgical Resection |
|---|---|---|
| What it is | A single‑group trial procedure using microwave energy to ablate liver metastases with real‑time confirmation that a safety margin fully surrounds the tumor | Surgical removal of colorectal liver metastases with curative intent |
| Role in the trial | Investigational, single‑group intervention aiming to destroy metastases while confirming safety margin | Not part of trial arm but represents current curative approach |
| Primary use | Local treatment aimed at eradicating small colorectal liver metastases when resection may be limited | Resection remains the main curative local treatment for resectable liver metastases |
| How it is performed | Percutaneous or intraoperative microwave energy applied under imaging, with real‑time confirmation that a margin covers the tumor | Surgical removal of metastases through open or laparoscopic liver resection |
| Evidence status | Evidence pending; this trial tests local control and survival outcomes but results not yet available | Better understood long‑term outcomes with 5‑year survival rates of 30–60 % in well‑selected patients |
| Important limitations | Local recurrence risk uncertain; long‑term outcomes not established | Not an option for patients with poorly resectable metastases or insufficient liver reserve |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single procedure with follow-up imaging within 4 to 8 weeks
Participants undergo microwave ablation of 1 to 3 colorectal liver metastases using an FDA cleared or CE Marked device to create a minimum ablation margin of 5.0 mm.
1 ablation procedure visit and 2 imaging visits within 8 weeks post-procedure
Duration - Up to 90 days
Participants are monitored for ablation margin assessment, potential repeat ablation if margins are insufficient, and for safety events up to 90 days after ablation.
Approximately 3 follow-up visits within 90 days
Duration - Up to 24 months
Participants are followed for local tumor progression, hepatic disease-free survival, and overall survival up to 24 months after treatment.
Periodic visits for assessments during 24 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Constantinos T Sofocleous, Matthew R Callstrom, Elena N Petre...
https://pubmed.ncbi.nlm.nih.gov/41013745/Society of Interventional Oncology
Lead Sponsor